CN108047140A - The preparation method of HMG-CoA reductase inhibitor and its intermediate - Google Patents
The preparation method of HMG-CoA reductase inhibitor and its intermediate Download PDFInfo
- Publication number
- CN108047140A CN108047140A CN201810049147.8A CN201810049147A CN108047140A CN 108047140 A CN108047140 A CN 108047140A CN 201810049147 A CN201810049147 A CN 201810049147A CN 108047140 A CN108047140 A CN 108047140A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- preparation
- compound shown
- adds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C)(C(C[C@@]1OC(C)(C)O[C@](C*C2=**=**2c2ccccc2)C1)=O)OC Chemical compound C*(C)(C(C[C@@]1OC(C)(C)O[C@](C*C2=**=**2c2ccccc2)C1)=O)OC 0.000 description 1
- CZDJAEDYXUMLIB-KGLIPLIRSA-N CC1(C)O[C@H](CS(C2=NNN2c2ccccc2)(=O)=O)C[C@H](CC(NOC)=O)O1 Chemical compound CC1(C)O[C@H](CS(C2=NNN2c2ccccc2)(=O)=O)C[C@H](CC(NOC)=O)O1 CZDJAEDYXUMLIB-KGLIPLIRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The preparation method of HMG CoA reductase inhibitors and its intermediate, is related to a kind of preparation method of statins compounds, and synthetic route is as follows：It introduces a kind of with H2The noval chemical compound of the amide bond of N O R groups is as key intermediate, using the intermediate, in JULIA into alkene step, E/Z is made selectively to be improved, and synthetic route is succinct, key intermediate is all solid, reaction is launched convenient for purifying products and Material Science, so as to obtain high purity product.
Description
Technical field
The present invention relates to a kind of preparation methods of statins compounds, more particularly to hypolipidemic rosuvastain calcium
Preparation method.
Background technology
Rosuvastain calcium is a kind of selective HMG-CoA reductase inhibitor, is developed by Astrazeneca AB,
In the multiple countries and regions listing such as the U.S., Japan, Europe, China, chemical name for it is double-[E-7- [4- (the fluorine-based phenyl of 4-)-
6- isopropyls -2- [methyl (mesyl) amino]-pyrimidine -5- bases] (3R, 5S) -3,5- dihydroxy heptyl -6- olefin(e) acids] calcium salt (2：
1),
Chemical structural formula is as follows：
Route at present on the synthesis report of rosuvastain calcium is more, such as Chinese patent application
Route disclosed in CN200510038203.0, CN1821242 or CN103025727, the synthetic route of these patent application publications
Tediously long, process conditions are harsh, and manufacturing cost is high, and synthetic route multistep synthetic intermediate for grease and needs column chromatography, no
It is suitble to large-scale industrial production；And synthesis technology is reacted using Witig mostly, it is poor to Z/E selectively controls.
In general, current synthetic route has complex synthetic route, and intermediate is difficult for grease
It is purified with Quality Control, and E/Z is selectively low, purifying products difficulty is big, it is necessary to repeatedly purify, whole low yield.
The content of the invention
In view of the shortcomings of the prior art, the present invention provides a kind of variation route for preparing rosuvastain calcium and its intermediate.
One aspect of the present invention provides a kind of rosuvastain calcium, the preparation method of compound, synthetic route shown in formula (VI)
It is as follows：
It comprises the following steps：
Compound is in tetrahydrofuran (THF) shown in compound shown in step 1) formula (III) and formula (C3), in the work of highly basic
Compound shown in formula (IV) is made with lower reaction；
Step 2) adds in dilute acid soln into compound shown in formula (IV), when stirring 1 to 24 is small after add in dilute alkaline soln, then
It carries out post-processing compound water solution shown in obtained formula (V) after stirring several minutes；
Compound water solution shown in formula made from step 3) toward step 2) (V) adds in purified water, and temperature control is to 30-35 DEG C, drop
Add calcium acetate solution, be added dropwise, stir 30min, temperature control is to 10-30 DEG C, centrifugation, and purifying water wash drying obtains Rosuvastain
The wet fine work of spit of fland calcium.
Further, the step 1) highly basic is tert-butyl alcohol alkali metal compound, such as potassium tert-butoxide, sodium tert-butoxide, often
Compound shown in the formula (III) of equivalent, it is necessary to 3.0 to 4.5eq highly basic, the highly basic is cooled to -40 ± 5 under nitrogen protection
DEG C be added dropwise；The addition of the THF is compound shown in the formula (III) of 15mL/1g；The reaction temperature of step 1) is 20-30 DEG C.
Further, the reaction temperature of step 2) is 25-30 DEG C, and step 2) carries out in THF, and the dosage of THF is 6-
Compound shown in the formula (IV) of 10mL/1g；The dilute acid soln is 3%HCl, and addition is about 0.5eq；The dilute alkaline soln is
5%NaOH, dosage are about 1.5eq.
Further, the dosage of the step 3) purified water is compound, the second shown in the formula (IV) of 12-14mL/1g
Sour calcium solution mass fraction is 3.5%.
Another aspect of the present invention provides the preparation method of compound shown in formula (III), and synthetic route is as follows：
It comprises the following steps：
Step a) adds in compound and dichloromethane (DCM), dosage shown in formula (I) at 25 ± 5 DEG C into reactor
Compound shown in the formula (I) of 4.5mL/1g, stirring, is added portionwise 1.2eq CDI, stirred under nitrogen atmosphere 1h is cooled to 10 ± 5
DEG C, the O- methyl hydroxylamine hydrochlorides of 1.1eq are added portionwise, addition finishes, and is warming up to 25 ± 5 DEG C, and reaction is to finishing.
Step b) adds in isopropanol into step a) products therefroms, and dosage is compound shown in the formula (I) of 4mL/1g, is stirred
Dissolving adds in 0.05eq ammonium heptamolybdates, is cooled to 10 ± 5 DEG C, and 30% hydrogen peroxide of 4eq is slowly added dropwise, is added dropwise, continues to stir
Mix 1h, temperature control is reacted to 25 ± 5 DEG C.
The synthetic route that the present invention prepares rosuvastain calcium introduces one kind with H2N-O-R (R is alkyl) group
The noval chemical compound of amide bond, using the intermediate, in JULIA into alkene step, makes E/Z selectively obtain as key intermediate
Improve, and synthetic route is brief, key intermediate is all solid, and reaction is launched convenient for purifying products and Material Science, so as to
To high yield, high purity product, finished product only need to once purify HPLC purity up to 99.9%, and each step yield is more than 90%.
Ultralow temperature and expensive highly basic are needed mostly into alkene reaction on JULIA, material used in this synthetic route is all valency at present
Lattice are cheap or the reagent that is routinely easy to get, and are reacted at a relatively high temperature into alkene reaction, make it is easy to operate, it is at low cost, it is dirty
Contaminate small, process stabilizing.
Invention additionally discloses following noval chemical compounds：
In the context of the invention, CDI is N, N'- carbonyl dimidazoles；Eq represents equivalent；10 ± 5 DEG C represent 5 DEG C to 15 DEG C
Specific embodiment
In order to which those skilled in the art is made to more fully understand technical scheme, it is non-that some are disclosed further below
Limiting embodiment, the present invention is described in further detail.
The preparation of compound shown in 1 formula of embodiment (III)
1. the preparation of compound shown in formula (II)
30 DEG C add in compound (319g) and DCM (800mL) shown in formula (I) into the mono- neck flasks of 50mL, and stirring adds in batches
Enter CDI (136g), stirred under nitrogen atmosphere 1h is cooled to 10 ± 5 DEG C, and O- methyl hydroxylamine hydrochlorides (53.9g) are added portionwise, add
Enter to finish, be warming up to 30 DEG C, react to compound≤2.0% shown in formula (I), add in water (800mL), stir 15min, liquid separation is abandoned
Water phase, organic phase are washed again through water (800mL), and 35 DEG C of vacuum distillations remove dichloromethane, and gained oil product is directly used in
The next step.
1H-NMR, 400MHz, CDCl3, ppm：1.35 (d, 6H), 1.85 (m, 2H), 3.49 (s, 3H), 3.59 (m, 1H),
3.72 (m, 1H), 3.19 (dd, 2H), 6.79 (t, 2H), 7.58 (d, 1H), 7.63 (q, 2H), 7.69 (d, 1H), 7.0-8.0
(1H), 7.58 (d, 1H)
2. the preparation of compound shown in formula (III)
Isopropanol (800mL) is added in step products therefrom upwards, stirring and dissolving adds in ammonium heptamolybdate (47.8g), is cooled to
10 ± 5 DEG C, 30% hydrogen peroxide (292.6g) is slowly added dropwise, is added dropwise, continue to stir 1h, temperature control is reacted to 25 ± 5 DEG C to Asia
Sulfone≤5.0% after reaction, is cooled to 10 ± 5 DEG C, saturated sodium bisulfite solution (250mL) is added dropwise, is added dropwise, 40 ± 5
DEG C vacuum distillation remove isopropanol, add in 5% sodium bicarbonate solution (1000mL), stir 1h, filtering, filter cake after water wash,
It is recrystallized at 75 ± 5 DEG C through ethyl acetate/n-heptane system (600mL/1000mL), 50 DEG C of vacuum drying 8h of wet product obtain formula
(III) compound 286.3g shown in, HPLC peak area 90.45%.
1H-NMR, 400MHz, CDCl3, ppm：1.35(d,6H),3.48(s,3H),3.59(m,1H),5.06(s,2H),
6.79 (t, 2H), 7.25 (m, 2H), 7.63 (q, 2H), 7.69 (d, 1H), 8.07 (d, 1H), 7.0-8.0 (b, 1H)
The preparation of compound shown in 2 formula of embodiment (IV)
Compound (100g) shown in formula (III), compound (82.50g) and THF shown in formula (C3) are added in into reaction kettle
(1500L) is cooled to -37 DEG C under nitrogen protection, the tert-butyl alcohol (formula (III) of 200mL/1g of potassium tert-butoxide (100.5g) is added dropwise
Shown compound) and THF (compound shown in the formula (III) of 200mL/1g) mixed solution, be added dropwise, stir 3h, temperature control
To 25 ± 5 DEG C, 15% sodium chloride solution (1000mL) is added in, stirs 15min, liquid separation abandons water phase, KBH is added in into organic phase4
(10g) adds in 15% sodium chloride solution (1000mL), and water phase is abandoned in liquid separation, and 40 DEG C of vacuum distillations remove organic solvent, add in acetic acid
Ethyl ester (1000mL), stirring and dissolving, through water washing twice (500mLx2), vacuum distillation, products therefrom is through ethyl acetate/positive heptan
Alkane=300mL/300mL recrystallizations, 50 DEG C of vacuum drying 8h of wet product, is made compound shown in formula (IV), 122.9g, HPLC peaks face
Product 98.6%.1H-NMR, 400MHz, CDCl3, ppm：1.23-1.27(m,7H),1.40(s,3H),1.50(s,3H),2.42-
2.80(dd,2H),3.20(s,3H),3.37(q,1H),3.57(s,3H),3.70(s,3H),4.41(m,2H),5.44(dd,
1H),6.49(d,2H),7.08(t,2H),7.64(q,2H),7.0-8.0(b,1H)
3 rosuvastain calcium of embodiment, the preparation of compound shown in formula (VI)
1. the preparation of compound shown in formula (VI)
28 DEG C add in compound (2.0g) and THF (16) stirring and dissolving shown in formula (IV) into reaction kettle, add in 3%HCl
(1.5g) adds in 5%NaOH (4.5g) after stirring 17h, is stirred for vacuum distillation removing THF after 3h, adds in purified water (6mL),
PH=9-10 is adjusted through 3%HCl, methyl tertiary butyl ether(MTBE) (18mL) is added in into reaction kettle, stirs 30min, liquid separation, water phase is again
It washed once through methyl tertiary butyl ether(MTBE) (16mL), 40 ± 5 DEG C of vacuum distillation gained aqueous are directly used in the next step.
2. rosuvastain calcium, the preparation of compound shown in formula (V)
Purified water (20mL) is added in step gained aqueous upwards, 3.5% calcium acetate (12.3g) is added dropwise to 30-35 DEG C in temperature control
Solution is added dropwise, and stirs 30min, and temperature control is to 20 ± 10 DEG C, centrifugation, and purifying water wash drying obtains the wet essence of rosuvastain calcium
Product, 50 ± 5 DEG C are dried under vacuum to moisture≤2.5%, 3.37g, and HPLC peak areas 99.9% are specifically shown in Table 1：
Table 1：
| As a result | Retention time | Peak area | Peak area % |
| 1 | 27.14 | 119860744 | 99.906 |
| 2 | 30.51 | 71735 | 0.060 |
| 3 | 45.03 | 40667 | 0.034 |
The foregoing is only a preferred embodiment of the present invention, is not intended to limit the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should all be included in the protection scope of the present invention.
Claims (6)
1. a kind of rosuvastain calcium, the preparation method of compound, synthetic route are as follows shown in formula (VI)：
It comprises the following steps：
Compound shown in step 1) formula (III) in tetrahydrofuran, is reacted with compound shown in formula (C3) under the action of highly basic
Compound shown in formula (IV) is made；
Step 2) adds in dilute acid soln into compound shown in formula (IV), when stirring 1 to 24 is small after add in dilute alkaline soln, be stirred for
It carries out post-processing compound water solution shown in obtained formula (V) after several minutes；
Compound water solution shown in formula made from step 3) toward step 2) (V) adds in purified water, and second is added dropwise to 30-35 DEG C in temperature control
Sour calcium solution, is added dropwise, and stirs 30min, and temperature control is to 10-30 DEG C, centrifugation, and purifying water wash drying obtains rosuvastain calcium
Wet fine work.
2. preparation method as described in claim 1, the step 1) highly basic is potassium tert-butoxide, sodium tert-butoxide, the formula per equivalent
(III) compound shown in, it is necessary to 3.0 to 4.5eq highly basic, the highly basic is cooled to -40 ± 5 DEG C of dropwise additions under nitrogen protection；
The addition of the tetrahydrofuran is compound shown in the formula (III) of 15mL/1g；The reaction temperature of step 1) is 20-30 DEG C.
3. preparation method as described in claim 1, the reaction temperature of step 2) is 25-30 DEG C, and step 2) carries out in THF,
The dosage of THF is compound shown in the formula (IV) of 8mL/1g；The dilute acid soln is 3%HCl, addition 0.4eq；It is described dilute
Aqueous slkali is 5%NaOH, dosage 1.5eq.
4. preparation method as described in claim 1, the dosage of the step 3) purified water is formula (IV) shownization of 10mL/1g
Object is closed, the calcium acetate solution mass fraction is 3.5%.
5. the preparation method of compound, synthetic route are as follows shown in formula (III)：
It comprises the following steps：
Step a) adds in compound and dichloromethane shown in formula (I) at 25 ± 5 DEG C into reactor, and dosage is the formula of 4mL/1g
(I) compound shown in, stirring, is added portionwise 1.2eq CDI, stirred under nitrogen atmosphere 1h is cooled to 10 ± 5 DEG C, is added portionwise
The O- methyl hydroxylamine hydrochlorides of 1.0eq, addition finish, and are warming up to 25 ± 5 DEG C, and reaction is to finishing.
Step b) adds in isopropanol into step a) products therefroms, and dosage is compound shown in the formula (I) of 4mL/1g, and stirring is molten
Solution adds in 0.06eq ammonium heptamolybdates, is cooled to 10 ± 5 DEG C, and 30% hydrogen peroxide of 4eq is slowly added dropwise, is added dropwise, continues to stir
1h, temperature control are reacted to 25 ± 5 DEG C.
6. compound：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810049147.8A CN108047140A (en) | 2018-01-18 | 2018-01-18 | The preparation method of HMG-CoA reductase inhibitor and its intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810049147.8A CN108047140A (en) | 2018-01-18 | 2018-01-18 | The preparation method of HMG-CoA reductase inhibitor and its intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108047140A true CN108047140A (en) | 2018-05-18 |
Family
ID=62127819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810049147.8A Pending CN108047140A (en) | 2018-01-18 | 2018-01-18 | The preparation method of HMG-CoA reductase inhibitor and its intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108047140A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454216A (en) * | 2019-10-21 | 2020-07-28 | 山东理工职业学院 | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011104725A2 (en) * | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
| CN103025727A (en) * | 2010-07-01 | 2013-04-03 | 柳韩洋行 | Process For The Preparation Of HMG-COA reductase inhibitors and intermediates thereof |
| CN103804414A (en) * | 2014-03-07 | 2014-05-21 | 凯莱英医药集团（天津）股份有限公司 | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium from rosuvastatin calcium |
-
2018
- 2018-01-18 CN CN201810049147.8A patent/CN108047140A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011104725A2 (en) * | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
| CN103025727A (en) * | 2010-07-01 | 2013-04-03 | 柳韩洋行 | Process For The Preparation Of HMG-COA reductase inhibitors and intermediates thereof |
| CN103804414A (en) * | 2014-03-07 | 2014-05-21 | 凯莱英医药集团（天津）股份有限公司 | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium from rosuvastatin calcium |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454216A (en) * | 2019-10-21 | 2020-07-28 | 山东理工职业学院 | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
| CN111518034A (en) * | 2019-10-21 | 2020-08-11 | 山东理工职业学院 | Preparation method of statin compound and intermediate thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104876888B (en) | It is used to prepare the method and intermediate of drug agents | |
| CN109320498A (en) | The bromo- 1-(3- chloro-2-pyridyl of 3-) -1H- pyrazoles -5- formic acid alkyl ester preparation method | |
| CN114989043A (en) | Synthesis method of boc-L-glutamic acid dimethyl ester | |
| CN108047140A (en) | The preparation method of HMG-CoA reductase inhibitor and its intermediate | |
| CN110642790B (en) | Preparation method of rosuvastatin calcium and intermediate thereof | |
| CN105646285B (en) | One kind dimension Lactel sieve intermediate and its preparation method and application | |
| JP2009107996A (en) | Triester-vinylether, and method for preparing the same | |
| EA036663B1 (en) | Method for preparing azoxystrobin | |
| CN104860980B (en) | It is a kind of to be used to synthesize intermediate of Ezetimibe and its preparation method and application | |
| KR20190111043A (en) | Method of Preparation of Purine Derivatives | |
| CN108299216A (en) | The preparation method of 2,6- of one kind dimethyl-l-tyrosine | |
| CN106966889A (en) | One kind (E) β, γ alkene-carboxylic acid's derivatives and preparation method thereof | |
| CN108623455A (en) | A kind of intermediate of cardiotonic agents | |
| CN107663170B (en) | Method for preparing besifloxacin intermediate compound | |
| CN105820064A (en) | Synthetic method of biphenylyl alaninol derivative and intermediate | |
| CN104496737B (en) | A kind of method of synthesis α amine formyl ethyl fluoroacetate compounds | |
| CN104761420B (en) | Method for synthesizing amide from methyl aromatic hydrocarbon and amine in water phase | |
| JP4667593B2 (en) | Process for producing 2-alkyl-2-adamantyl (meth) acrylates | |
| CN109678787A (en) | A kind of new HCV virus NS3/4A inhibitor synthetic intermediate and synthetic method | |
| CN106543040B (en) | A kind of synthetic method of medicine intermediate carbamate compounds | |
| CN107118144B (en) | Reduction preparation process of ezetimibe and intermediate thereof | |
| CN105820106B (en) | The preparation method of Aiweimopan intermediate | |
| US20190135725A1 (en) | Process for preparing substituted crotonic acids | |
| CN110407902B (en) | Method for removing 17-acetoxyl group from steroid compound | |
| CN110862335B (en) | Preparation method of VEGFR2 selective inhibitor SU1498 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180518 |